StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.06+0.02 (+1.92%)

Close on Nov 17, 2026Market cap $106.36MP/E –Yield –

Cellectis cash

Cash and short-term investments held at the end of each period.

Cellectis's cash was $35.59M at Jun 30, 2026. For fiscal 2025 it was $61.53M, down 57.0% from the year before. Over ten years it grew -15.8% a year on average. The highest annual figure on record is $451.50M in fiscal 2018.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$61.53M-57.0%
FY2024Dec 31, 2024$143.25M+4.8%
FY2023Dec 31, 2023$136.71M+46.7%
FY2022Dec 31, 2022$93.22M-49.8%
FY2021Dec 31, 2021$185.64M-23.0%
FY2020Dec 31, 2020$241.15M-29.2%
FY2019Dec 31, 2019$340.52M-24.6%
FY2018Dec 31, 2018$451.50M+76.1%
FY2017Dec 31, 2017$256.38M+0.7%
FY2016Dec 31, 2016$254.57M-25.6%
FY2015Dec 31, 2015$342.11M+150.8%
FY2014Dec 31, 2014$136.40M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$35.59M-76.1%
Q4 FY2025Dec 31, 2025$61.53M-55.0%
Q2 FY2025Jun 30, 2025$59.81M-29.1%
Q4 FY2024Dec 31, 2024$143.25M+53.7%
Q2 FY2024Jun 30, 2024$149.04M+15.1%
Q4 FY2023Dec 31, 2023$136.71M-26.4%
Q2 FY2023Jun 30, 2023$84.39M-66.0%
Q4 FY2022Dec 31, 2022$93.22M-61.3%
Q2 FY2022Jun 30, 2022$129.44M-50.4%
Q4 FY2021Dec 31, 2021$185.64M-45.5%
Q2 FY2021Jun 30, 2021$248.23M-37.5%
Q4 FY2020Dec 31, 2020$241.15M-46.6%
Q2 FY2020Jun 30, 2020$260.71M+1.7%
Q4 FY2019Dec 31, 2019$340.52M+33.8%
Q2 FY2019Jun 30, 2019$396.97M+16.0%
Q4 FY2018Dec 31, 2018$451.50M+231.0%
Q4 FY2017Dec 31, 2017$256.38M–
Q4 FY2016Dec 31, 2016$254.57M–
Q4 FY2015Dec 31, 2015$342.11M–
Q4 FY2014Dec 31, 2014$136.40M–

More Cellectis figures

See a number that looks wrong?